# Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

> **NCT01857193** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 132 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ribociclib (LEE011)
- **DRUG:** Exemestane
- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT01857193
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-06
- **Primary completion:** 2018-03-14
- **Final completion:** 2020-04-16
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857193, "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01857193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*